Cargando…

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study

AIMS: Although dyspnoea is the most common cause of admission for acute heart failure (AHF), more needs to be known about its clinical course and prognostic significance. METHODS AND RESULTS: The Pre-RELAX-AHF study randomized 232 subjects with AHF to placebo or four doses of relaxin and evaluated e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metra, Marco, Teerlink, John R., Felker, G. Michael, Greenberg, Barry H., Filippatos, Gerasimos, Ponikowski, Piotr, Teichman, Sam L., Unemori, Elaine, Voors, Adriaan A., Weatherley, Beth Davison, Cotter, Gad
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944016/ https://www.ncbi.nlm.nih.gov/pubmed/20732868 http://dx.doi.org/10.1093/eurjhf/hfq132

Ejemplares similares

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
por: Voors, Adriaan A, et al.
Publicado: (2014)

Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
por: Biegus, Jan, et al.
Publicado: (2019)

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study
por: Meyer, Sven, et al.
Publicado: (2016)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF
por: Liu, Licette C. Y., et al.
Publicado: (2016)

Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF
por: Davison, Beth A., et al.
Publicado: (2011)

Relaxin, a pleiotropic vasodilator for the treatment of heart failure
por: Teichman, Sam L., et al.
Publicado: (2008)

Relaxin: Review of Biology and Potential Role in Treating Heart Failure
por: Teichman, Sam L., et al.
Publicado: (2010)

Vasodilators in the treatment of acute heart failure: what we know, what we don’t
por: Metra, Marco, et al.
Publicado: (2008)

Worsening renal function in acute heart failure in the context of diuretic response
por: Emmens, Johanna E., et al.
Publicado: (2021)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023)

Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure
por: Damman, Kevin, et al.
Publicado: (2017)

Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC)
por: Metra, Marco, et al.
Publicado: (2022)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
por: Al-Mubarak, Ali A., et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023)

Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial: Differential Response in Acute Heart Failure
por: Liu, Licette C. Y., et al.
Publicado: (2017)

A combined clinical and biomarker approach to predict diuretic response in acute heart failure
por: ter Maaten, Jozine M., et al.
Publicado: (2015)

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
por: Pandhi, Paloma, et al.
Publicado: (2021)

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021)

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
por: Packer, Milton, et al.
Publicado: (2021)

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
por: Filippatos, Gerasimos, et al.
Publicado: (2016)

Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2021)

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure
por: Ponikowski, Piotr, et al.
Publicado: (2014)

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) trial design
por: Bartunek, Jozef, et al.
Publicado: (2015)

Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
por: de Koning, Marie-Sophie L. Y., et al.
Publicado: (2023)

Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) trial
por: ter Maaten, Jozine M., et al.
Publicado: (2022)

Cardiopoietic stem cell therapy in ischaemic heart failure: long‐term clinical outcomes
por: Bartunek, Jozef, et al.
Publicado: (2020)

Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications
por: Sokolska, Justyna Maria, et al.
Publicado: (2018)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Acute Decompensated Heart Failure Update
por: Teerlink, John R, et al.
Publicado: (2015)

Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies
por: Anker, Stefan D., et al.
Publicado: (2015)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v8vhlivst1ndjd0l3p08lf5q4u